For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Lifting of Prescription Period Limitation for Antiplatelet Agent Efient® 3.75mg/5mg Tablets in Japan

Tokyo, Japan (June 1, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the antiplatelet agent Efient® 3.75mg/5mg Tablets (JAN: Prasugrel Hydrochloride), which was launched in Japan in May 2014, has had its prescription period limitation of 14 days lifted based on a notification received from the Japanese Ministry of Health, Labour and Welfare.

Efient is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited. The results of clinical trials in Japanese patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI) demonstrated that Efient reduces the incidence of ischemic events from the perioperative period of PCI by rapidly reducing platelet aggregation activity.

Through the lifting of the prescription period limitation of Efient, Daiichi Sankyo aims to benefit even more patients and healthcare professionals involved with ischemic heart disease therapy.

Product Overview in Japan

Product Name	Efient® 3.75mg/5mg Tablets
Generic name (JAN)	Prasugrel Hydrochloride
Price Listing	Efient 3.75mg: ¥282.70 per tablet Efient 5mg: ¥359.80 per tablet
Indication	Prasugrel is indicated for the following ischemic cardiac diseases, which require percutaneous coronary intervention (PCI): ・Acute coronary syndromes (Unstable angina, Non ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction) ・Stable angina, Old myocardial infarction
Dosage and administration	Prasugrel should be initiated orally with a single 20-mg loading dose and then continued at a 3.75-mg once daily dose for adults.
Approval date	March 24, 2014
Manufacturing and marketing	Daiichi Sankyo Company, Limited